Biotech Values

[jq1234]

SNY said Thursday it does not expect to meet a production milestone that would have triggered a $1 payout to holders of the contingent value right (CVR) of recently acquired Genzyme Corp.

The $1 milestone is tied to production levels of two Genzyme drugs: Fabrazyme agalsidase beta for Fabry's disease and Cerezyme imiglucerase for Gaucher's disease. Sanofi does not expect to meet end-of-year supply goals for Fabrazyme. Sanofi did say it is supplying Cerezyme globally at normal dosing levels.

http://www.bizjournals.com/boston/news/2011/07/28/genzyme-misses-milestone-drug.html?ana=yfcpc